Table 1.

Study Design for Study A-1, A-2, and Study B.

Study (-Phase)	n Animals (M/F)	Dose(s) (mg/kg IV, mg IT)	Samples/Data Collected	Time Points	Analysis Methods
A-1	6 animals (3M/4F)	1.5 mg/kg IV	Blood, CSF	5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 1 day, 2 days, 3 days post dose	ELISA
A-1	6 animals per dose (3M/4F)	1.5 mg, 4.5 mg, 13.5 mg IT	Blood, CSF	5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 1 day, 2 days, 3 days post dose	ELISA
A-2	2 animals per time point (1M/1F)	14.5 mg IT	Blood, CSF, Tissues	predose and 1 h, 4 h, 8 h, 1 day, 3 days, 7 days post dose	ELISA, enzyme activity
B	4 animals (2M/2F)	1 mg/kg IV	Blood, whole body PET	t = 0 and every 30 min 1–5 h, then at 1 day and 2 days	Radioactivity HPLC, PET
B	4 animals (2M/2F)	3 mg IT	Blood, whole body PET	t = 0 and every 30 min 1–5 h, then at 1 day and 2 days	Radioactivity HPLC, PET

Intravenous (IV); intrathecal (IT); cerebral spinal fluid (CSF); enzyme linked immunosorbent assay (ELISA); high performance liquid chromatography (HPLC), positron emission tomography (PET).